Dr. Raúl Insa, SOM Biotech CEO, gave an interview to Labiotech.eu, leading digital media covering the European Biotech industry, read by 100000+ monthly visitors. In this interview, Dr. Insa explained the mission of SOM Biotech, advantages of drug repurposing and aspects of drug development for Orphan diseases. SOM Biotech’s CEO also talked about the current…

Dr. Luca Signorile, Senior computational chemist at SOM Biotech, will be attending the 12th Annual Global Discovery to Development Innovation Forum (GDDIF) that will take place in Amsterdam on 14th – 15th of May. The Annual GDDIF is the leading pharmaceutical Research & Development summit for pharma decision makers, scientific leaders, and solutions experts. Taking a…

Dr. Raúl Insa, SOM Biotech CEO, attended the second campus of the 2018-2019 TechShare programme organized by Euronext and Nova School of Business and Economics (Nova SBE). The event took place on 15th and 16th of March in Lisbon, Portugal. TechShare is an educational and mentoring programme which aims to familiarize the CEOs of Bio-Tech companies with the financial markets.…

Dr. Santiago Esteva, Head of Clinical Operations at SOM Biotech, will be presenting at the 3rd Annual Clinical Trials Summit that will take place in Barcelona next April 29 and 30. He will be discussing about the relationship of small biotech companies and CROs from SOM’s perspective, highlighting the challenges in selecting a CRO to conduct the…

On March 8, 2019, the SOMCT02 clinical trial successfully closed recruitment, marking 100% fulfillment of its targeted number of patients. SOM Biotech is very proud of all the efforts being done by the participating sites, and we are expecting to achieve good results from this clinical trial which will cover a great medical need in…

SOM Biotech has just closed a financing round of 7 million euros led by a holding company belonging to a European family with a long tradition in the pharmaceutical sector which will give the opportunity to get a facilitated access to pharma network. Several of the current partners of SOM Biotech have also taken the…